BiotechTube

Briquilimab

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urticaria Chronic

Conditions

Urticaria Chronic

Trial Timeline

Nov 26, 2024 → Sep 30, 2026

NCT ID
NCT06736262

About Briquilimab

Briquilimab is a phase 2 stage product being developed by Jasper Therapeutics for Urticaria Chronic. The current trial status is active. This product is registered under clinical trial identifier NCT06736262. Target conditions include Urticaria Chronic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT06736262Phase 2Active
NCT06592768Phase 1Terminated
NCT06353971Phase 1/2Terminated
NCT06162728Phase 1/2Active

Competing Products

20 competing products in Urticaria Chronic

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 1/2
33
CT-P39 + EU-approved XolairCelltrionPhase 3
77
OmalizumabCelltrionPre-clinical
23
LY3454738 + PlaceboEli LillyPhase 2
52
AZD1981 + PlaceboAstraZenecaPhase 2
52
Benralizumab + Placebo and BenralizumabAstraZenecaPhase 2
52
LOU064NovartisPhase 3
77
Ligelizumab + OmalizumabNovartisPhase 3
77
Ligelizumab + PlaceboNovartisPhase 1
33
OmalizumabNovartisPhase 2
52
canakinumabNovartisPhase 2
52
LOU064NovartisPhase 2
52
Omalizumab (Xolair) + PlaceboNovartisPhase 2/3
65
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo armNovartisPhase 2
52
LOU064 (blinded) + placeboNovartisPhase 3
77
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injectionNovartisPhase 3
77
omalizumab + omalizumabNovartisPhase 3
77

Other Products from Jasper Therapeutics

BriquilimabPhase 1/2
33
BriquilimabPhase 1/2
33
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1/2
33
JSP191Phase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1
25